Business profile: deutsche gmbh inc. Was established in 1981 as xinjiang kampuchea textiles co. Ltd. And changed to deutsche gmbh co. In 2016 following the completion of the major asset reorganization. The company, based in the hoang district of beijing, is a high-technology enterprise dedicated to the development, production and marketing of medicines, with diversified layouts in the area of greater health. The core advantage of r & d is strong: the company has a r & d team of nearly 200 people, and r & d inputs account for about 10 per cent of revenue. The core subsidiary, garin pharmaceuticals, is a high-technology enterprise with a number of gmp certified pharmaceutical production bases and testing centres with strong r & d and production capacity. Rich product lines: the products cover areas such as chemicals, bioinnovators, bio-likes and dna innovations. The tablets include the cardiovascular system drugs of ale, nilla, hydrochloric acid and tamarindium; the bioinnovation tablets in cbd for pulmonary artery hypertensive rare diseases; dna; the innovation plate in vgx-3100 anti-hpv pre-cancer drugs, etc. In addition, companies are involved in such areas as polypylene applications, industrial cannabis applications and health care. A sound financial position: as of june 2024, company assets totalled $5,365 million, net assets were $5,228 million, asset liabilities were 2. 55 per cent, cash assets had a balance of $2. 775 billion, a healthy financial position that provided firm financial security for the company's continued development and innovation. Brand influence: corporations occupy a major market position in the big health industry, and the core product, ala, has a high brand profile and market occupancy rate, a home-based home-based emulation of atavitatin calcium, and the country's first product to be evaluated through the atovatin calcium concordance. Social responsibility: as a socially responsible enterprise, german health is actively involved in the public good, contributing to social harmony and progress through donations, consultations, health education, etc., and promoting brand image and social prestige. For the future: companies will continue to embrace the concept of development of “dreaming and healthy futures”, increase their investment in research and development, promote the development and production of innovative medicines, actively expand international markets, and strive to provide better quality, efficient and accessible health services for people, and sustain growth in the field of biomedicine。